189 related articles for article (PubMed ID: 27741355)
1. Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors.
Verma V; Shostrom VK; Kumar SS; Zhen W; Hallemeier CL; Braunstein SE; Holland J; Harkenrider MM; S Iskhanian A; Neboori HJ; Jabbour SK; Attia A; Lee P; Alite F; Walker JM; Stahl JM; Wang K; Bingham BS; Hadzitheodorou C; Decker RH; McGarry RC; Simone CB
Cancer; 2017 Feb; 123(4):688-696. PubMed ID: 27741355
[TBL] [Abstract][Full Text] [Related]
2. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
5. Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis.
Verma V; Shostrom VK; Zhen W; Zhang M; Braunstein SE; Holland J; Hallemeier CL; Harkenrider MM; Iskhanian A; Jabbour SK; Attia A; Lee P; Wang K; Decker RH; McGarry RC; Simone CB
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):778-785. PubMed ID: 28244414
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database.
Shioyama Y; Onishi H; Takayama K; Matsuo Y; Takeda A; Yamashita H; Miyakawa A; Murakami N; Aoki M; Matsushita H; Matsumoto Y; Shibamoto Y;
Technol Cancer Res Treat; 2018 Jan; 17():1533033818783904. PubMed ID: 29983096
[TBL] [Abstract][Full Text] [Related]
7. Is stereotactic body radiotherapy an alternative to surgery in early stage non small cell lung cancer?
Yaprak G; Ozan Seseogullari O; Dogan Akaslan B; Isik N
J BUON; 2019; 24(4):1619-1625. PubMed ID: 31646817
[TBL] [Abstract][Full Text] [Related]
8. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
9. Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.
Kennedy WR; Gabani P; Nikitas J; Robinson CG; Bradley JD; Roach MC
Radiother Oncol; 2020 Jan; 142():230-235. PubMed ID: 31481272
[TBL] [Abstract][Full Text] [Related]
10. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
Ogawa Y; Shibamoto Y; Hashizume C; Kondo T; Iwata H; Tomita N; Ogino H
Radiat Oncol; 2018 Jul; 13(1):136. PubMed ID: 30055636
[TBL] [Abstract][Full Text] [Related]
11. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
12. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
13. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer.
Verma V; Simone CB; Allen PK; Gajjar SR; Shah C; Zhen W; Harkenrider MM; Hallemeier CL; Jabbour SK; Matthiesen CL; Braunstein SE; Lee P; Dilling TJ; Allen BG; Nichols EM; Attia A; Zeng J; Biswas T; Paximadis P; Wang F; Walker JM; Stahl JM; Daly ME; Decker RH; Hales RK; Willers H; Videtic GM; Mehta MP; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):362-371. PubMed ID: 28011047
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Large (> 5 cm) Non-Small-Cell Lung Cancer.
Peterson J; Niles C; Patel A; Boujaoude Z; Abouzgheib W; Goldsmith B; Asbell S; Xu Q; Khrizman P; Kubicek GJ
Clin Lung Cancer; 2017 Jul; 18(4):396-400. PubMed ID: 28040379
[TBL] [Abstract][Full Text] [Related]
15. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
16. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
Kilburn JM; Lester SC; Lucas JT; Soike MH; Blackstock AW; Kearns WT; Hinson WH; Miller AA; Petty WJ; Munley MT; Urbanic JJ
J Thorac Oncol; 2014 Apr; 9(4):572-6. PubMed ID: 24736084
[TBL] [Abstract][Full Text] [Related]
17. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis.
Cummings MA; Ma SJ; Hermann G; Serra L; Syed Y; Malhotra HK; Chen Y; Milano MT; Gomez-Suescun JA; Singh DP; Singh AK
Clin Lung Cancer; 2018 Nov; 19(6):511-517. PubMed ID: 30131257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
